OKYO Pharma Limited - Dr. Napoleone Ferrara to Serve on the SAB
("OKYO" or the "Company")
Appointment of Dr.
OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that that Dr.
research on understanding the role of angiogenesis and vascular endothelial growth factor (VEGF) in cancer development, led to the discovery that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. This pioneering research led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis®), which has also been approved as a therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the development of therapies for these blinding disorders. When Lucentis® (Ranibizumab) received FDA approval in late
| || || |
+44 (0)20 7495 2379
| || |
+ 44 (0)20 3981 4173
For further information, please visit the Company's website at www.okyopharma.com.
This information is provided by RNS, the news service of the
Quick facts: Okyo Pharma Limited
Market Cap: £72.3 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE